Skip to main content
OpenTrials
Completed

NCT Number: NCT02875873

Balanced Solution Versus Saline in Intensive Care Study

A 2x2 factorial randomized study to evaluate the effect of a balanced crystalloid solution compared with 0.9% saline, and of rapid vs. slow infusion on clinical outcomes of critically ill patients

Completed

Looking for future studies?

Notify Me

Key information

About this study

Pragmatic, multicenter, 2x2 factorial randomized study. Severe patients admitted to the ICU at moderate to high risk for death or acute kidney injury will be randomly allocated to receive a balanced crystalloid solution (Plasma-Lyte®) or 0.9% saline and to receive crystalloids by rapid bolus infusion (999 mL/h) or slow infusion (333 mL/h) whenever plasma expansion is needed.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

(all three):

  • Need for plasma expansion, and the clinician considers that Plasma-Lyte® or 0.9% saline are equally appropriate for patients, with no specific indications or contraindications for any of the fluids or for rapid or slow infusion.
  • Patients not expected to be discharged on the day after their admission.
  • At least one of the following risk factors for acute renal injury:
  • Age ≥ 65 years
  • Hypotension (mean arterial pressure [MAP] < 65 mmHg or systolic blood pressure [SBP] < 90 mmHg) or use of vasopressors
  • Sepsis
  • Use of invasive mechanical ventilation or of continuous noninvasive mechanical ventilation (including high-flow nasal cannula) > 12 hours
  • Oliguria (< 0.5 mL/kg/hour for ≥ 3 hours)
  • Serum creatinine ≥ 1.2 mg/dL for women or ≥ 1.4 mg/dL for men
  • Liver cirrhosis or acute liver failure

Exclusion criteria

(any of the below):

  • Age < 18 years
  • Acute renal failure treated with renal replacement therapy (RRT) or expected to require RRT within the next 6 hours
  • Severe hyponatremia (serum sodium ≤ 120 mmol/L)
  • Severe hypernatremia (serum sodium ≥ 160 mmol/L)
  • Death considered imminent and inevitable within 24 hours
  • Patients with suspected or confirmed brain death
  • Patients under exclusive palliative care
  • Patients previously enrolled in the BaSICS study

Treatment and study plan

Plasma-Lyte

Drug

Plasma-Lyte will be used for fluid expansion and maintenance

saline 0.9%

Drug

Saline 0.9% will be used for fluid expansion and maintenance

Other names: Normal Saline

Slow infusion speed

Other

Whenever fluid expansion is deemed necessary by the attending physician, infusion speed will be set at 333 mL/h. NOTE: This intervention will not be blinded.

Fast Infusion Speed

Other

Whenever fluid expansion is deemed necessary by the attending physician, infusion speed will be set at 999 mL/h. NOTE: This intervention will not be blinded.

Primary outcomes

  1. Mortality

    Time frame: 90 days

Secondary outcomes

  1. Renal failure requiring renal replacement therapy

    Time frame: 90 days

  2. Renal Injury (KDIGO equal or greater than 2)

    Time frame: Days 3 and 7

  3. Hepatic, cardiac, neurological, coagulation, and respiratory dysfunctions (assessed by Sequential Organ Failure Assessment [SOFA] scores)

    Time frame: Days 3 and 7

  4. Mechanical ventilation free days

    Time frame: 28 days

Other outcomes

  1. Intensive Care Unit Mortality

    Time frame: At ICU discharge, up to 90 days

  2. Hospital Mortality

    Time frame: At Hospital discharge, up to 90 days

  3. Length of Intensive Care Unit stay

    Time frame: At ICU discharge, up to 90 days

  4. Length of hospital stay

    Time frame: At hospital discharge, up to 90 days

  5. Quality of Life at 6 months

    Time frame: 180 days

    Assessed using EQ-5D. Will only be performed in a subsample of all included patients (10%)

Sponsors and collaborators

Lead sponsor

Hospital do Coracao

Other

Registry information

Acronym: BaSICS

Important dates

Study start
2017
Primary completion
2020
Study completion
2021
First posted
Aug 23, 2016
Registry last updated
Apr 19, 2021

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.